Pierre Bories

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laëtitia Vercellino, Roberta Di Blasi, Salim Kanoun et al. · Blood Advances · 2020 · 387 citations · Full text

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi et al. · Nature Medicine · 2022 · 343 citations · Full text

Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

Gandhi Damaj, Alain Duhamel, Marie Robin et al. · Journal of Clinical Oncology · 2012 · 204 citations · Full text

Risk stratification for invasive aspergillosis in immunocompromised patients

Raoul Herbrecht, Pierre Bories, Jean‐Charles Moulin et al. · Annals of the New York Academy of Sciences · 2012 · 144 citations

Fungal Diversity, Invasive Aspergillosis, Autoimmune Disease +10

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy et al. · Blood · 2022 · 131 citations · Full text

Aggressive B-cell Lymphoma, Immunology, Pathology +18